EU Approves €400 Million in Aid for Sanofi’s New Insulin Plant in Frankfurt
Brussels has cleared the way for the pharmaceutical manufacturer to replace its insulin production at Frankfurt-Höchst with a modern €1.3 billion facility.
The European Commission has approved €400 million in EU state aid for Sanofi-Aventis Deutschland GmbH (Sanofi) to build a new insulin factory at its site at Industriepark Frankfurt-Höchst. The September 8 decision, backed by the German federal government, the State of Hessen, and the City of Frankfurt, clears the way for a project Sanofi announced in 2024 with a total investment of €1.3 billion.
The aid is structured as compensation for a public service obligation and covers Sanofi-Aventis Deutschland GmbH’s net costs of securing insulin supply, according to the European Commission. In return, the company must complete the new factory by the end of 2032, produce at least 1.1 metric tons of insulin a year at the site through 2042, hold a reserve of one metric ton of insulin active substance through 2024, and prioritize European Economic Area (EEA) markets during shortages.
About 6,500 people work at Sanofi’s Frankfurt site, including more than 4,000 in its insulin operations. The new facility will replace the company’s existing insulin production at the site, span roughly 36,000 square meters, and continue supplying about 80 countries with 20 insulin products.
Frankfurt-Höchst is the only site producing human insulin in the EEA, and one of just two insulin production sites in the region. Without the funding, Sanofi would have closed its insulin active ingredient production at the German site – a decision that would have reduced the security of insulin supply across the EEA at a time when several manufacturers are already redirecting production capacity toward GLP-1 diabetes and weight-loss drugs.
“From the very beginning, we have consistently pushed for Sanofi to secure insulin production in Frankfurt-Höchst for the long term,” said Kaweh Mansoori, Hessian Minister of Economic Affairs. “The European Commission’s decision brings us a decisive step closer to this goal. We are retaining a strategically important value chain in Hessen, strengthening supply resilience in Germany and Europe, and giving highly qualified employees at the site a long-term perspective. At the same time, the investment shows that active industrial policy can make a difference when the state, the federal government, and the municipality work together for a location.”